Meeting
2019 ASCO Annual Meeting
An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
Authors
Mark R. Middleton
Churchill Hospital, Oxford, United Kingdom
Mark R. Middleton , Joseph J. Sacco , Jaime R. Merchan , Brendan D. Curti , Ari M. Vanderwalde , Anna Claire Olsson-Brown , Francesca Aroldi , Nicos Fotiadis , Scott Baum , Robert S. Coffin , Howard Kaufman , Kevin J. Harrington
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT03767348
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2671)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2671
Abstract #
TPS2671
Poster Bd #
301b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
First Author: Omid Hamid
Poster
2023 ASCO Annual Meeting
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.
First Author: Jiajian Liu
Poster
2022 ASCO Annual Meeting
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.
First Author: Kevin Joseph Harrington
Poster
2022 ASCO Annual Meeting
An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors.
First Author: Kevin Joseph Harrington